GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » Scaled Net Operating Assets

Puma Biotechnology (Puma Biotechnology) Scaled Net Operating Assets : 0.24 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Puma Biotechnology's operating assets for the quarter that ended in Mar. 2024 was $107.0 Mil. Puma Biotechnology's operating liabilities for the quarter that ended in Mar. 2024 was $52.4 Mil. Puma Biotechnology's Total Assets for the quarter that ended in Dec. 2023 was $230.5 Mil. Therefore, Puma Biotechnology's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.24.


Puma Biotechnology Scaled Net Operating Assets Historical Data

The historical data trend for Puma Biotechnology's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology Scaled Net Operating Assets Chart

Puma Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.09 0.13 0.24 0.31

Puma Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.35 0.33 0.34 0.24

Competitive Comparison of Puma Biotechnology's Scaled Net Operating Assets

For the Biotechnology subindustry, Puma Biotechnology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Scaled Net Operating Assets falls into.



Puma Biotechnology Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Puma Biotechnology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(134.589-65.596)/222.059
=0.31

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=230.528 - 95.939
=134.589

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=177.086 - 72.693 - 38.797
=65.596

Puma Biotechnology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(106.986-52.432)/230.528
=0.24

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=214.149 - 107.163
=106.986

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=163.167 - 60.429 - 50.306
=52.432

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Puma Biotechnology Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Puma Biotechnology (Puma Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Executives
Alan H Auerbach director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Alvin F Wong officer: Chief Scientific Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Maximo F Nougues officer: Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig officer: Chief Commercial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt officer: See Remarks C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Michael Patrick Miller director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Adrian Senderowicz director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Troy Edward Wilson director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes director
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce officer: SR VP, CLINICAL RESEARCH & DEV C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd director C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139